This review gives a comprehensive overview on recent developments in the classification of neoplastic lung lesions with lepidic growth patterns, comprising the adenocarcinoma (ADC) precursor lesions atypical adenomatous hyperplasia (AAH), adenocarcinoma in situ (AIS), and minimally invasive adenocarcinoma (MIA) as well as lepidic predominant adenocarcinoma (LPA).
INTRODUCTION
Adenocarcinoma (ADC) is the most common subtype of lung cancer. Over the last decade, clinical, radiological, and pathological efforts including molecular and morphological analyses have revealed multiple novel disease classifiers. These findings need to be translated and integrated into the clinical setting in order to improve patients' outcome.
Morphology-based categorization of ADC has recently gained attention, as clinically relevant findings have been put forward in this field. To account for this, in 2011, a revised classification for pulmonary ADC was introduced by joint international, multidisciplinary lung cancer specialists representing the International Association for the Study of Lung Cancer (IASLC), the American Thoracic Society (ATS), and the European Respiratory Society (ERS) [1] . Major aspects of this classification comprise a revised concept of ADC precursor lesions and a semi-quantitative assessment of ADC growth pattern. This classification has been validated independently in different cohorts worldwide and was proven to be an important, in some studies even stage-independent, predictor of survival [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . First studies indicate that the classification is reproducibly applicable [15] [16] [17] . Most recently, retrospective analysis of more than 6000 resected ADCs of the Japan lung cancer registry underscored the independent prognostic impact of histomorphological subtyping [18 & ]. In advanced tumor stages, the semi-quantitative assessment of growth pattern was also suggested to be of predictive value for adjuvant treatment [12, 19] . However, there are also some conflicting data claiming that assessment of growth patterns does not add relevant prognostic information to established staging systems [20] . In this review, we focus on the most recent findings and clinical implications of the IASLC/ATS/ERS classification of ADC with emphasis on tumors with lepidic growth, which comprise the ADC precursor lesions atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ (AIS) as well as minimally invasive adenocarcinoma (MIA) and lepidic predominant adenocarcinoma (LPA).
THE LEPIDIC PATTERN
Until it was suggested to discontinue the use of the term 'bronchiolo-alveolar carcinoma' (BAC) [1] , BAC had been used for a broad spectrum of morphologically and molecular diverse tumors, thus leading to confusion and a lack of comparability of study data. The respective growth patterns of former BACs in the stricter sense are now designated as 'lepidic'. There have been considerable discussions about the origin of the term 'lepidic' itself, which were most recently resolved in a historical overview [21 & ]. 'Lepidic' refers to neoplastic tumor cell growth along pre-existing alveolar structures in a flat manner, without forming papillary or micropapillary structures (Fig. 1) . Lepidic growth is usually accompanied by thickened alveolar walls but typically lacks inflammation. Stromal, vascular or pleural invasion must be absent. The different tumors with lepidic growth are now classified in a continuous spectrum ranging from AAH to AIS to MIA and, ultimately, LPA (Table 1) .
ATYPICAL ADENOMATOUS HYPERPLASIA AND ADENOCARCINOMA IN SITU
AAH is a localized, small (usually 0.5 cm or less) lepidic proliferation of mildly to moderately atypical type II pneumocytes and/or Clara cells lining alveolar walls, replacing normal bronchioloalveolar epithelium of the terminal respiratory unit and, sometimes, respiratory bronchioles. AAH is an
KEY POINTS
The morphological IASLC/ATS/ERS classification of pulmonary ADCs is of high prognostic relevance and reproducibly applicable.
The novel concept of a continuum of lepidic lung tumors is a consequent step from the tumor-biologic point of view and its prognostic meaning has been validated independently in multiple studies around the globe.
Lepidic tumor growth is mirrored by specific characteristics in computed tomography images (ground glass opacities), thus allowing for a combined assessment of histomorphology and imaging data for an optimized classification of lepidic neoplasms. In AIS, the size of the nuclei is further increased, the nuclei are usually more hyperchromatic, and there is also a higher degree of variability in cellular and nuclear size and shape (pleomorphism). Although there is no invasive tumor growth, stromal thickening as a reaction to the neoplastic proliferation is evident.
accepted precursor lesion for ADC and frequently observed as a coincident finding in both neoplastic and nonneoplastic resection specimens. There is a continuum of morphologic changes between AAH and AIS, making a clear-cut distinction of both entities challenging. In AIS, cellular atypia might be more pronounced than in AAH. Overall, cell density, pleomorphism, and cell size can aid in the delineation. Furthermore, AAH must be separated from reactive pneumocyte hyperplasia. AIS is defined as a small to moderately sized (3 cm), solitary neoplastic lesion with pure lepidic growth. Typical cytologic features of AIS include bland, small, monomorphous nuclei with fine chromatin and inconspicuous pinpoint nucleoli. Nuclear groves and nuclear pseudo-inclusions can be prominent. A cell arrangement in orderly strips and small flat monolayers is also a characteristic feature of AIS. Cellular atypia is usually slightly more pronounced than in AAH; in addition, these lesions are usually larger than 0.5 cm. AIS is further subdivided into nonmucinous and mucinous variants, but according to literature and in our own experience virtually all cases are nonmucinous. AIS has been demonstrated to be associated with a 100% 5-year disease-free survival in multiple studies [3, 7, 11, 13, 14 ]. However, one recent study reported a slightly impaired 5-year overall survival of 98% [27] .
MINIMALLY INVASIVE ADENOCARCINOMA
MIA is a small to moderately sized solitary lesion (3 cm) with lepidic pattern and circumscribed invasive foci. Mucinous variants of MIA are rare. The number of invasive foci is variable; however, most often only one distinct area of microinvasion is present. By definition, the invasive areas must be 5 mm or smaller in greatest dimension in any one focus. The invasive component to be measured in MIA is defined as being of any histological pattern other than lepidic (i.e. acinar, papillary, micropapillary and/or solid) or comprising single nests of tumor cells infiltrating myofibroblastic stroma. The category MIA is not applied to tumors invading lymphatics, blood vessels, or pleura or to tumors containing necrosis. When multiple independent tumors are present, AIS and MIA should only be diagnosed if the lesions are regarded as synchronous primaries rather than intrapulmonary metastases. Approximately one third of ADCs have a significant lepidic component and of these nearly one third are believed to be minimally invasive [28] .
MIA has been demonstrated to have a 100% 5-year disease-free survival in multiple studies [3, 7, 13 [29] [30] [31] . One study reported a slightly diminished 5-year overall survival of 98% [27] .
The delineation of invasive foci in MIA from AIS with sclerotic septal widening or alveolar collapse can be challenging, as the latter two morphologic states might resemble acinar tumor growth. To ease the evaluation of parenchymal invasion, in some cases the use of elastic stains demonstrating a destruction of the elastic structures can be helpful to differentiate true invasion from alveolar collapse [28] . However, early invasion will not necessarily 
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Note that the morphology criteria represent a continuum; clear-cut delineation on the basis of cytomorphology alone is not advisable.
result in a destruction of elastic fibers. Furthermore, a recent study pointed out that one must be aware not to misinterpret biopsy-site changes from prior biopsies as tumor-related stromal reactions [32] . Regardless of these shortcomings, the introduction of MIA as a new entity placed between AIS and LPA is a logical step from the tumor-biological point of view and helpful for pathologists in cases in which the features for stromal invasion versus alveolar collapse are controversial. However, in the strict sense, the definitive delineation of microinvasive foci is not critical from the clinical viewpoint (see below). In contrast, exact delineation of MIA from LPA is of utmost importance, as both entities are associated with a significantly different prognosis. In addition, Yeh et al. [33 & ] demonstrated that not only invasion per se but also different stromal invasion categories in combination with specific ADC patterns were associated with variations in patient survival. Another work quoted that even small micropapillary components in an MIA might be associated with a worse prognosis [28] . The acinar (91%) and the papillary pattern (9%) were described as the predominant invasive components in a series of 43 MIAs [26 && ], which further complicates the delineation of MIA from AIS, as both patterns are the ones most readily confused with lepidic tumor growth (see below). This might also explain why there was only a fair reproducibility in the delineation of invasive from noninvasive ADC patterns among international pulmonary pathologists [15] . In frozen sections, the differentiation of AIS from MIA is difficult because of multifactorial reasons (e.g. intraoperative consultation of more than one pathologist necessary; more than one sample of frozen sections needed) as demonstrated by root cause analysis of 224 consecutive cases [34] .
LEPIDIC PREDOMINANT ADENOCARCINOMA
LPA typically consists of slightly to moderately atypical neoplastic cells growing along the surface of alveolar walls. Architecture and cytomorphology are comparable with the criteria described for AIS and MIA. However, at least one invasive focus measuring more than 5 mm in greatest dimension must be present. The diagnosis of LPA rather than MIA is also made if the tumor invades lymphatics, blood vessels, or pleura and if the tumor contains necrosis. The average percentage of the lepidic pattern in LPA was recently reported to be 50% (range: 40-85%) with acinar (81%) and papillary (17%) as the predominant accompanying invasive components [26 && ]. In several retrospective studies, 5-year disease-free survival of LPA ranged between 85.7 and 100% [3,13, ]. As multifocality is a typical feature of tumors with predominant lepidic growth, the prognostic impact of synchronous lesions was analyzed by different groups. In a series of 39 patients with multifocal ground glass lesions and negative lymph nodes, Gu et al. [35 & ] recently reported a 100% overall survival after anatomic resection of the dominant tumor and wedge resection of all other accessible ground glass opacities (GGO), which is in line with data from previous studies [36] [37] [38] [39] .
The proportion of the lepidic growth in LPA is of high prognostic value. Stratification for survival in dependence of ADC diameter is better when instead of the overall tumor diameter only the adjusted nonlepidic ('invasive') tumor diameter is taken into account [12] . This observation strengthens comparable findings by Yoshizawa et al. [13] and was also underscored by recent data of two series of n ¼ 603 [40 & ] and n ¼ 191 [24 & ] stage I ADC in which the 'invasive' size was of higher prognostic impact than the total tumor size. In both studies, the total tumor size even failed to reach prognostic relevance, whereas the invasive tumor size was found to be an independent prognosticator in multivariate analysis. This is supported by data of Zhang et al. [41] , who analyzed 215 small peripheral ADC, and Xu et al. [28] , who analyzed 87 resected ADCs with lepidic growth. Both studies found that histomorphological subtyping is more reliable to predict the N0 status than the tumor size. In addition, the size of the invasive foci has been demonstrated as an independent predictor of survival for pulmonary ADC in preceding studies [42] .
If a noninvasive pattern is present in a small biopsy, it should be referred to as lepidic growth. The diagnosis of AIS or MIA cannot be firmly established without entire histologic sampling of the tumor. To achieve this, patients necessarily must be subjected to surgery. For lesions suspicious for AIS or MIA with a diameter of larger than 3 cm (based on imaging analyses; compare Fig. 2) , the term 'lepidic predominant ADC' should be applied including a comment that an invasive component cannot be excluded [43 & ].
DIAGNOSTIC REPRODUCIBILITY OF THE LEPIDIC GROWTH
With a mean correlation coefficient of 0.78, lepidic growth is associated with a good interobserver agreement [17] . However, the delineation from papillary or acinar growth has been found challenging, but training sessions improve the interobserver agreement [16] . Furthermore, cases with obscuring inflammation as well as lepidic involvement of emphysematous areas can be difficult with respect to correct pattern interpretation. This underlines the need for international efforts in this regard, which was further emphasized by an interobserver study on the reproducibility of histopathological subtypes and invasion demonstrating that more precise definitions and better education on the interpretation of existing terminology are required to improve proper diagnosis of purely in-situ disease [15] . Furthermore, Thunnissen et al. [44] analyzed threedimensional reconstructions of pulmonary ADCs from serial sections for the influence of surgical atelectasis on the diagnosis of a 'lepidic' pattern. It was shown that for reliable ADC subtyping, pathologists must be aware of artifacts because of compressed or collapsed tissue to avoid misclassification of the lepidic pattern as papillary growth.
LEPIDIC GROWTH AND IMAGING MODALITIES
Lepidic growth can be predicted by imaging modalities to a certain extent. In computed tomography (CT), lepidic growth is mirrored by GGO, thus allowing the rough estimation of the 'lepidic' fraction of a tumor (e.g. pure GGO, part-solid nodule) already prior to surgery or in advanced tumor stages when only palliative treatment is feasible [11,45,46 & ,47] . This has been demonstrated to be of prognostic value, especially in early-stage lung ADC [48] [49] [50] [51] [52] [53] . On univariate analysis, the presence of a positive air bronchogram, size of nodule, and mass of nodule were significant factors that differentiated invasive ADC from AIS or MIA. On multivariate analysis, size and mass of nodule were significant determinants for invasive ADC [54] . In a series of 114 lesions with pure GGO, Ichinose et al. [55] reported that after morphological workup, 14% of the cases were diagnosed as MIA and only 12% as invasive cancer. Differential diagnosis of part-solid nodules includes focal inflammation, focal fibrosis, and organizing pneumonia. Furthermore, maximum standardized uptake values (SUVmax) on positron emission tomography (PET)/CT and mean apparent diffusion coefficient values have been reported to correlate well with the histologic differentiation of pulmonary ADC [56] . In pure GGO lesions, PET-positive tumors are associated with foci of invasion [55] . [5] .
From a clinical point of view, a classification should reflect the patients' prognosis to allow for tailored treatment decisions. This has been achieved with the novel classification. With respect to prognosis of tumors with lepidic growth, it is of utmost importance to delineate between MIA and LPA, whereas the differentiation of AIS and MIA from each other seems to have no prognostic relevance. Concerning staging, AIS and MIA are classified as pTis and pTmia, respectively, and should not be considered for multiple nodule upstaging. For a definite separation of the lepidic tumors, surgical resection is a prerequisite, which, in cases in which a definite classification is necessary, hampers the use of alternative treatment options.
Advances in imaging allow for an early detection of lung cancer, while increasing numbers of precursor lesions are expected to be diagnosed in the future. A large trial demonstrated that small nodules smaller than 10 mm or smaller than 500 mm 3 that are clearly 100% pure GGO lesions on CT might be considered for close follow-up rather than immediate resection [57] . Whether some of these lesions can be treated by limited resection is a prevailing question and a subject of intensive investigations [58] . However, although most cases of AIS or MIA will likely be cured by complete resection [26 && ], a small percentage of LPA will recur. Thus, it is of utmost importance to further characterize these lesions in a multidisciplinary setting in order to identify criteria allowing for risk-adjusted treatment decisions.
With respect to predictive biomarkers used for patient stratification, nonmucinous lepidic growth is significantly associated with mutations in the epidermal growth factor receptor but not V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations [25, [59] [60] [61] [62] . Tumors with mucinous lepidic growth and papillary projections, now designated as invasive mucinous ADC, are associated with KRAS mutations [27, [62] [63] [64] ; however, these tumors now form a separate entity and are not part of the lepidic tumor spectrum anymore.
CONCLUSION
Taken together, the validity and clinical importance of the novel concept of a continuum of lepidic lung tumors have been confirmed by clinical, radiological, morphological, and molecular data. Thereby, it has evolved into a valuable tool to aid in clinical decision-making.
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